• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定和验证基于血液的儿科炎症性肠病诊断脂质组学特征。

Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease.

机构信息

School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.

出版信息

Nat Commun. 2024 Jun 3;15(1):4567. doi: 10.1038/s41467-024-48763-7.

DOI:10.1038/s41467-024-48763-7
PMID:38830848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11148148/
Abstract

Improved biomarkers are needed for pediatric inflammatory bowel disease. Here we identify a diagnostic lipidomic signature for pediatric inflammatory bowel disease by analyzing blood samples from a discovery cohort of incident treatment-naïve pediatric patients and validating findings in an independent inception cohort. The lipidomic signature comprising of only lactosyl ceramide (d18:1/16:0) and phosphatidylcholine (18:0p/22:6) improves the diagnostic prediction compared with high-sensitivity C-reactive protein. Adding high-sensitivity C-reactive protein to the signature does not improve its performance. In patients providing a stool sample, the diagnostic performance of the lipidomic signature and fecal calprotectin, a marker of gastrointestinal inflammation, does not substantially differ. Upon investigation in a third pediatric cohort, the findings of increased lactosyl ceramide (d18:1/16:0) and decreased phosphatidylcholine (18:0p/22:6) absolute concentrations are confirmed. Translation of the lipidomic signature into a scalable diagnostic blood test for pediatric inflammatory bowel disease has the potential to support clinical decision making.

摘要

需要改善的生物标志物用于儿科炎症性肠病。在这里，我们通过分析来自发现队列的新发病例治疗-naïve儿科患者的血液样本，并在独立的起始队列中验证发现，确定了儿科炎症性肠病的诊断脂质组学特征。脂质组学特征由仅乳糖基神经酰胺（d18:1/16:0）和磷脂酰胆碱（18:0p/22:6）组成，与高敏 C 反应蛋白相比，可改善诊断预测。向特征添加高敏 C 反应蛋白不会改善其性能。在提供粪便样本的患者中，脂质组学特征和粪便钙卫蛋白（胃肠道炎症标志物）的诊断性能没有明显差异。在第三个儿科队列中进行调查后，证实了乳糖基神经酰胺（d18:1/16:0）浓度增加和磷脂酰胆碱（18:0p/22:6）浓度降低的发现。将脂质组学特征转化为用于儿科炎症性肠病的可扩展诊断血液测试具有支持临床决策的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/c8c3b7e55cef/41467_2024_48763_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/91da0d2d1e2f/41467_2024_48763_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/177b3d8304c5/41467_2024_48763_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/c7e0a66696df/41467_2024_48763_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/9cd4fba79ae4/41467_2024_48763_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/327a8c803f1e/41467_2024_48763_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/c8c3b7e55cef/41467_2024_48763_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/91da0d2d1e2f/41467_2024_48763_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/177b3d8304c5/41467_2024_48763_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/c7e0a66696df/41467_2024_48763_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/9cd4fba79ae4/41467_2024_48763_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/327a8c803f1e/41467_2024_48763_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b507/11148148/c8c3b7e55cef/41467_2024_48763_Fig6_HTML.jpg

相似文献

1
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease.鉴定和验证基于血液的儿科炎症性肠病诊断脂质组学特征。
Nat Commun. 2024 Jun 3;15(1):4567. doi: 10.1038/s41467-024-48763-7.
2
The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.粪便钙卫蛋白在疑似小儿炎症性肠病中的诊断准确性。
Am J Gastroenterol. 2012 Jun;107(6):941-9. doi: 10.1038/ajg.2012.33. Epub 2012 Feb 28.
3
Fecal Calprotectin as a Screening Marker for Inflammatory Bowel Disease.粪便钙卫蛋白作为炎症性肠病的筛查标志物。
Indian Pediatr. 2019 Mar 15;56(3):249-250.
4
Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data.除症状外使用实验室标志物诊断儿童炎症性肠病：个体患者数据的荟萃分析
JAMA Pediatr. 2017 Oct 1;171(10):984-991. doi: 10.1001/jamapediatrics.2017.1736.
5
Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.粪便钙卫蛋白在小儿炎症性肠病中的应用：系统评价。
Dig Dis Sci. 2013 Feb;58(2):309-19. doi: 10.1007/s10620-012-2347-5. Epub 2012 Aug 17.
6
Avoid Endoscopy in Children With Suspected Inflammatory Bowel Disease Who Have Normal Calprotectin Levels.对于疑似炎症性肠病但钙卫蛋白水平正常的儿童，避免进行内镜检查。
J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):47-9. doi: 10.1097/MPG.0000000000000939.
7
Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms.粪便钙卫蛋白能很好地预测有胃肠道症状儿童的结肠直肠炎症。
J Pediatr Gastroenterol Nutr. 2005 Apr;40(4):450-5. doi: 10.1097/01.mpg.0000154657.08994.94.
8
Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.儿童粪便钙卫蛋白水平与组织学检查结果的相关性比与宏观内镜检查结果的相关性更为紧密。
Clin Lab. 2014;60(12):1993-2000. doi: 10.7754/clin.lab.2014.140203.
9
[Assessment of fecal calprotectin concentration as inflammatory marker in inflammatory bowel diseases in children--preliminary report].[儿童炎症性肠病中粪便钙卫蛋白浓度作为炎症标志物的评估——初步报告]
Pol Merkur Lekarski. 2010 Oct;29(172):241-6.
10
Test Strategies to Predict Inflammatory Bowel Disease Among Children With Nonbloody Diarrhea.用于预测非血性腹泻儿童炎症性肠病的检测策略。
Pediatrics. 2020 Aug;146(2). doi: 10.1542/peds.2019-2235. Epub 2020 Jul 21.

引用本文的文献

1
Mass-spectrometry based metabolomics: an overview of workflows, strategies, data analysis and applications.基于质谱的代谢组学：工作流程、策略、数据分析及应用概述
Proteome Sci. 2025 May 26;23(1):5. doi: 10.1186/s12953-025-00241-8.
2
Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype.抗整合素αvβ6 IgG抗体作为溃疡性结肠炎的诊断和预后标志物：一项定义特定疾病表型的横断面和纵向研究。
J Crohns Colitis. 2025 May 8;19(5). doi: 10.1093/ecco-jcc/jjaf062.
3
Microbiota and Inflammatory Markers: A Review of Their Interplay, Clinical Implications, and Metabolic Disorders.

本文引用的文献

1
Faecal metabolome and its determinants in inflammatory bowel disease.炎症性肠病的粪便代谢组及其决定因素。
Gut. 2023 Aug;72(8):1472-1485. doi: 10.1136/gutjnl-2022-328048. Epub 2023 Mar 23.
2
Serum Lipidomic Screen Identifies Key Metabolites, Pathways, and Disease Classifiers in Crohn's Disease.血清脂质组学筛查鉴定克罗恩病的关键代谢物、途径和疾病分类器。
Inflamm Bowel Dis. 2023 Jul 5;29(7):1024-1037. doi: 10.1093/ibd/izac281.
3
Mucosal and Plasma Metabolomes in New-onset Paediatric Inflammatory Bowel Disease: Correlations with Disease Characteristics and Plasma Inflammation Protein Markers.
微生物群与炎症标志物：它们的相互作用、临床意义及代谢紊乱综述
Int J Mol Sci. 2025 Feb 19;26(4):1773. doi: 10.3390/ijms26041773.
4
The Role of Topical Tacrolimus in the Management of Inflammatory Bowel Disease: A Comprehensive Review.局部用他克莫司在炎症性肠病治疗中的作用：一项综述
J Clin Med. 2024 Sep 18;13(18):5518. doi: 10.3390/jcm13185518.
黏膜和血浆代谢组学在儿童炎症性肠病中的新发病例：与疾病特征和血浆炎症蛋白标志物的相关性。
J Crohns Colitis. 2023 Apr 3;17(3):418-432. doi: 10.1093/ecco-jcc/jjac149.
4
Inflammatory Bowel Disease Is Associated With Prediagnostic Perturbances in Metabolic Pathways.炎症性肠病与代谢途径的诊断前紊乱有关。
Gastroenterology. 2023 Jan;164(1):147-150.e2. doi: 10.1053/j.gastro.2022.09.007. Epub 2022 Sep 17.
5
The Rising Burden of Inflammatory Bowel Disease in Denmark Over Two Decades: A Nationwide Cohort Study.丹麦二十年来炎症性肠病负担不断增加：一项全国性队列研究。
Gastroenterology. 2022 Dec;163(6):1547-1554.e5. doi: 10.1053/j.gastro.2022.07.062. Epub 2022 Aug 8.
6
Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study.遗传因素、免疫与微生物组对炎症性肠病预后的影响（IBD 预后研究）：哥本哈根 IBD 发病队列研究方案。
BMJ Open. 2022 Jun 27;12(6):e055779. doi: 10.1136/bmjopen-2021-055779.
7
Incidence and Prevalence of Paediatric Inflammatory Bowel Disease Continues to Increase in the South of England.英格兰南部儿科炎症性肠病的发病率和患病率持续上升。
J Pediatr Gastroenterol Nutr. 2022 Aug 1;75(2):e20-e24. doi: 10.1097/MPG.0000000000003511. Epub 2022 Jun 6.
8
Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review.21世纪儿童期起病的炎症性肠病全球流行病学趋势：系统评价
Gastroenterology. 2022 Apr;162(4):1147-1159.e4. doi: 10.1053/j.gastro.2021.12.282. Epub 2022 Jan 5.
9
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.奥扎莫德用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
10
From bedside to bench-practical considerations to avoid pre-analytical pitfalls and assess sample quality for high-resolution metabolomics and lipidomics analyses of body fluids.从床边到实验台——避免分析前陷阱并评估体液高分辨率代谢组学和脂质组学分析样品质量的实用考虑因素。
Anal Bioanal Chem. 2021 Sep;413(22):5567-5585. doi: 10.1007/s00216-021-03450-0. Epub 2021 Jun 22.